Clinical-stage biopharmaceutical company developing treatments for diseases with unmet needs.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors tailored for diseases with significant unmet medical needs. Based in Cambridge, Massachusetts, the company focuses on advancing innovative therapies that target plasma kallikrein, a key enzyme involved in various conditions.
The company's robust product portfolio includes small molecule inhibitors of plasma kallikrein designed to address conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME). Among its leading products is KVD001, an advanced plasma kallikrein inhibitor that has successfully completed Phase II clinical trials for the treatment of DME, showcasing its potential in managing this challenging eye condition.
KalVista Pharmaceuticals is actively advancing sebelipase, currently in the Phase 3 KONFIDENT trial, as a promising oral therapy for on-demand treatment of HAE attacks. Additionally, the company is developing KVD824, an oral product candidate specifically designed to address the symptoms of HAE, underscoring its commitment to expanding treatment options for patients.
Innovating further, KalVista Pharmaceuticals is exploring Factor XIIa as part of its oral inhibitor program targeting enzymes implicated in HAE. This program, currently in the preclinical stage, highlights the company's dedication to pioneering advancements in therapeutic interventions for complex diseases. With a strategic focus on transformative therapies, KalVista Pharmaceuticals continues to push the boundaries of pharmaceutical innovation to improve patient outcomes globally.